Society guidelinesFocused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control
Section snippets
Predicting stroke risk
The Congestive Heart Failure, Hypertension, Age > 75, Diabetes Mellitus, and Prior Stroke or Transient Ischemic Attack (CHADS2) index2 assigns 1 point each for congestive heart failure, hypertension, age > 75, and diabetes, and 2 points for history of stroke or transient ischemic attack (TIA). It has been well validated, with the annual stroke rate increasing by about 2.0% for each 1-point increase in CHADS2 score (from 1.9% with a score of 0 to 18.2% with a score of 6).2, 3 A recent systematic
Updated risk/benefit assessment for dronedarone
The “A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter” (ATHENA) trial evaluated the safety and efficacy of dronedarone therapy in 4628 higher risk patients with AF or AFL (paroxysmal or persistent with sinus rhythm restoration planned).49 After a mean follow-up of 21 ± 5 months, there was a reduction in the
References (59)
- et al.
Canadian Cardiovascular Society atrial fibrillation guidelines 2010: implementing GRADE and achieving consensus
Can J Cardiol
(2011) - et al.
Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age > 75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme
Am Heart J
(2008) - et al.
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation
Chest
(2010) - et al.
Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter
Can J Cardiol
(2011) - et al.
A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice
J Thromb Haemost
(2011) - et al.
A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey
Chest
(2010) - et al.
Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort
J Thromb Haemost
(2011) - et al.
A new risk scheme to predict warfarin-associated hemorrhageThe ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study
J Am Coll Cardiol
(2011) - et al.
The primary and secondary prevention of coronary artery disease
Chest
(2008) - et al.
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
Lancet
(2009)
Antithrombotic therapy in atrial fibrillation
Chest
Relation of atrial fibrillation to glomerular filtration rate
Am J Cardiol
Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis from the auricula registry in sweden
Thromb Res
Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score
J Am Coll Cardiol
Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation
Am J Cardiol
Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients
Am J Kidney Dis
Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy
Kidney Int
Cardiovascular disease in chronic kidney diseaseA clinical update from kidney disease: improving global outcomes (KDIGO)
Kidney Int
Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management
Can J Cardiol
The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the Race II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study
J Am Coll Cardiol
Validation of clinical classification schemes for predicting strokeResults from the National Registry of Atrial Fibrillation
JAMA
Selecting patients with atrial fibrillation for anticoagulationStroke risk stratification in patients taking aspirin
Circulation
Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation
Stroke
Guidelines for the management of atrial fibrillationThe Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) [erratum in 2011;32:1172]
Eur Heart J
Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study
BMJ
Female gender is a risk factor for stroke in atrial fibrillation patients
Thromb Haemost
The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke riskThe TRENDS study
Circ Arrhythmia Electrophysiol
Subclinical atrial fibrillation and the risk of stroke
N Engl J Med
New antithrombotic agents-insights from clinical trials
Nat Rev Cardiol
Cited by (428)
Smartwatch monitoring for atrial fibrillation after stroke—The Pulsewatch Study: Protocol for a multiphase randomized controlled trial
2021, Cardiovascular Digital Health JournalThe 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation
2020, Canadian Journal of CardiologyThe Canadian Cardiovascular Society Atrial Fibrillation Guidelines Program: A Look Back Over the Last 10 Years and a Look Forward
2020, Canadian Journal of Cardiology
The disclosure information of the authors and reviewers is available from the CCS on the following websites: www.ccs.ca and www.ccsguidelineprograms.ca.
This statement was developed following a thorough consideration of medical literature and the best available evidence and clinical experience. It represents the consensus of a Canadian panel comprised of multidisciplinary experts on this topic with a mandate to formulate disease-specific recommendations. These recommendations are aimed to provide a reasonable and practical approach to care for specialists and allied health professionals obliged with the duty of bestowing optimal care to patients and families, and can be subject to change as scientific knowledge and technology advance and as practice patterns evolve. The statement is not intended to be a substitute for physicians using their individual judgement in managing clinical care in consultation with the patient, with appropriate regard to all the individual circumstances of the patient, diagnostic and treatment options available and available resources. Adherence to these recommendations will not necessarily produce successful outcomes in every case.
- ⁎
A complete list of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee primary and secondary panels is available in Supplemental Appendix S1.